

Antifungal activity of polyphenolic compounds against fluconazole-susceptible and -resistant *Candida* species

Harmed Fakhim¹, Bahar Mohamadi², Shima Gharibi¹, Medhi Rahimmalek³, Mahnaz Hosseini Rizi¹,
Mahsa Shelerangkon¹, Elahe Nasri¹, Fariba Dorostkar⁴, Antoni Szumny⁵, Afsane Vaezi^{4*}

¹Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

²Department of Microbiology, Tehran North Branch, Islamic Azad University, Tehran, Iran

³Department of Horticulture, College of Agriculture, Isfahan University of Technology, Isfahan, Iran

⁴Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

⁵Department of Food Chemistry and Biocatalysis, Wrocław University of Environmental and Life Sciences, Wrocław, Poland

Received: July 2024, Accepted: January 2025

ABSTRACT

Background and Objectives: The rapid emergence of resistant fungi is occurring worldwide, and this crisis has been attributed to the lack of new antifungal drug development. This issue emphasizes the need for innovation in finding novel antifungals. There is an increasing interest in using the natural products of plants with high biological activity as alternatives to synthetic drugs. This study aimed to evaluate the possible applicability of polyphenols as alternative antifungal drugs to treat resistant *Candida* infections.

Materials and Methods: A panel of fluconazole-resistant (n=14) and fluconazole-susceptible (n=26) clinical *Candida* isolates was obtained from the reference culture collection. The determination of the minimum inhibitory concentrations (MICs) of fluconazole, tannic acid, rosmarinic acid, gallic acid, chlorogenic acid, caffeic, ferulic, and p-coumaric was carried out following the Clinical and Laboratory Standards Institute (CLSI) guidelines.

Results: The MIC values of 40 *Candida* species isolates ranged from 0.25 to >64 µg/mL for polyphenolic compounds. The highest inhibitory effect against *Candida* species was observed with tannic acid, followed by fluconazole. Non-*albicans* *Candida* groups were more sensitive to tannic acid compared to *C. albicans* isolates. Significant differences were observed in the MICs of fluconazole and tannic acid against non-*albicans* *Candida* isolates.

Conclusion: The increasing antifungal resistance highlights the importance of evaluating new drugs that are more robust against resistance. This study suggests that tannic acid could be considered a novel antifungal agent for managing fungal infections, including multidrug-resistant non-*albicans* *Candida* infections.

Keywords: Tannic acid; Polyphenolic compounds; *Candida* species; Fluconazole resistance; Antifungal activity

*Corresponding author: Afsane Vaezi, Ph.D, Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Tel: +98-9354895243 Fax: +98-2186704717 Email: vaeziiafsane@gmail.com

INTRODUCTION

The worldwide emergence of antifungal resistance is a significant concern, particularly in immunosuppressed individuals, as delays in initiating adequate empiric therapy can lead to severe and life-threatening fungal infections (1, 2). Numerous reports have highlighted the growing problems of drug resistance in fungal pathogens (3-6). Recent studies indicate that various fungi contribute to drug resistance, with limited therapeutic options available for these infections (3, 7). Alarming, there has been a lack of new antifungals to combat the threat of drug-resistant fungal pathogens (8). The rise in antifungal resistance is a key factor in increased morbidity and mortality rates globally. Drug-resistant fungal infections can delay recovery, lead to higher medical costs, and pose significant treatment challenges. Drug-resistant *Candida* species have been implicated in over 34,000 cases and 1,700 deaths annually in the United States (9). The number of patients with invasive *Candida* infections caused by multidrug-resistant *C. auris* has increased dramatically, increasing from 329 cases in 2018 to 1,012 in 2021, according to emerging data (3, 9). Consequently, there is a critical need to develop novel therapeutic approaches, as the growing prevalence of drug-resistant fungi is contributing to millions of deaths worldwide. The rapid global emergence of resistant fungal has been attributed to the overuse of existing antifungals and lack of new antifungal development (10-12). This issue strongly highlights the critical need for innovation to discover novel chemical classes of antifungals to prevent cross-resistance and improve treatment outcomes. Phenolic compounds consist of an aromatic ring with one or more hydroxyl groups and can be simple phenolic molecules or polymerized compounds. There is an increasing interest in using natural products from plants with high biological activities as alternatives to synthetic drugs. Among these natural compounds, some polyphenolics ones are considered as the most health-related beneficial groups (13, 14). Phenolic compounds exhibit various activities, such as antioxidant, antidiabetic, anti-inflammatory, antiallergic, cardioprotective, antihypertensive, antithrombotic, anticancer, osteoprotective, neuroprotective, anti-aging, antibacterial, antitoxin, antiviral, and antifungal properties (13-18). Moreover, the majority of previous studies have highlighted the antifungal activity of whole plant extracts (15, 17). In this area of knowl-

edge, reports on the efficacy of phenolic compounds as antifungal agents remain limited. This study aimed to consider the potential applicability of polyphenols as alternative antifungal drugs for treating resistant *Candida* infections. Therefore, we examined the in vitro activity of tannic acid, gallic acid, rosmarinic acid, chlorogenic acid, caffeic, ferulic, and p-coumaric against a collection (n=40) of fluconazole-susceptible and -resistant *Candida* isolates.

MATERIALS AND METHODS

Polyphenolic standards. High-purity standards (more than 95%) were purchased from Sigma-Aldrich including tannic acid, gallic acid, rosmarinic acid, chlorogenic acid, caffeic, ferulic, and p-coumaric. stock solutions of polyphenolic compounds were prepared in dimethyl sulfoxide (DMSO) with the final concentration of DMSO >1%.

Antifungal susceptibility testing. A panel of fluconazole-resistant (n=14) and -susceptible (n=26) clinical *Candida* isolates, including *C. albicans* (n=13), *C. glabrata* (n=8), *C. tropicalis* (n=2), *C. parapsilosis* (n=8), *C. krusei* (n=3), *C. kefyr* (n=3), and *C. auris* (n=3), was obtained from the reference culture collection (19-24). All isolates were previously identified using both conventional and molecular methods. The *Candida* isolates were identified at the species level through polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and partial DNA sequencing of the ITS rDNA region with specific primers (23). Antifungal susceptibility testing was conducted according to the CLSI guidelines (25). The agents were dispensed into microdilution trays, with final concentration ranges of 0.063-64 µg/mL for both fluconazole (Pfizer, Groton, CT, USA) and the polyphenolic compound. The MIC endpoints were defined as a 50% reduction in growth compared to the agent-free growth control for both fluconazole and polyphenolics. All antifungal stock solutions were dissolved in DMSO, then diluted with RPMI 1640 medium (Sigma Chemical Co.) and dispensed into 96-well microdilution trays. Homogeneous suspensions were measured spectrophotometrically at 530 nm to determine percent transmission in the range 75-77. The final inoculum densities of the tested isolates were within the range of 0.5-2.5×10³ CFU/mL, as determined by quantitative colony counts on Sa-

bouraud glucose agar. *Candida parapsilosis* (ATCC 22019) and *C. krusei* (ATCC 6258) reference strains were included as quality controls. Plates were incubated at 35°C for 24 hours, and MIC values were visually determined. All tests were repeated twice for each isolate. Statistical analysis was performed using SPSS version 18.0 (IBM, New York, NJ, USA), with a P-value less than 0.05 considered statistically significant.

RESULTS

Table 1 summarises the MIC range, geometric mean (GM) MIC, MIC₅₀ and MIC₉₀ for phenolic compounds against 40 fluconazole-resistant and -susceptible clinical *Candida* isolates. The MIC values of 40 *Candida*

species isolates ranged from 0.25 to >64 µg/mL for polyphenolic compounds. Among the tested phenolic compounds, p-coumaric demonstrated the highest MICs (MIC range, 32->64 µg/mL; MIC₉₀, 64 µg/mL), followed by caffeic acid (MIC range, 32->64 µg/mL; MIC₉₀, 32 µg/mL) and ferulic acid (MIC range, 16->64 µg/mL; MIC₉₀, 16 µg/mL). However, tannic acid exhibited the potent activity (MIC range, 0.25->64 µg/mL; MIC₉₀, 16 µg/mL) against all *Candida* species isolates, in comparison to fluconazole (MIC range, 0.5->64 µg/mL; MIC₉₀, 32 µg/mL). Non-*albicans Candida* groups were more sensitive to tannic acid (MIC range, 0.25->64 µg/mL; GM MIC, 3.17 µg/mL) than *C. albicans* isolates (MIC range, 1-16 µg/mL; GM MIC, 6.46 µg/mL). Significant differences were observed in the MICs of fluconazole and tannic acid against non-*albicans Candida* isolates ($P < 0.05$).

Table 1. In vitro activities of polyphenolic compounds against clinical *Candida* species

Strains and polyphenolic compounds	Range	MICs (µg/ml)							
		MIC ₅₀ / MIC ₉₀	G mean	0.125	0.25	0.5	1	2	4
<i>Candida</i> species (40)									
Fluconazole	0.5- >64	4/16	4.28			4	8	7	4
Tannic acid	0.25- >64	4/16	4.07		1	3	2	5	11
Gallic acid	1- >64	16/19.2	10.88				1		
Rosmarinic acid	2- >64	8/25.6	9.18					1	
Chlorogenic acid	2- >64	8/20.8	8					1	2
Caffeic	32- >64	32/32	32						
Ferulic	16- >64	16/16	16						
P-coumaric	32- >64	32/64	44.47						
<i>Candida albicans</i> (13)									
Fluconazole	0.5- >32	2/8	2			3	2	2	1
Tannic acid	1- 16	8/16	6.46			1	4	5	
Gallic acid	1- >64	64/64	27.26			1			
Rosmarinic acid	2- >64	64/64	28.76					1	
Chlorogenic acid	2- >64	64/64	27.26					1	2
Caffeic	32- >64	32/32	33.75						
Ferulic	32- >64	32/64	37.55						
P-coumaric	32- >64	32/64	44.06						
Non- <i>Candida albicans</i> (27)									
Fluconazole	0.5- >64	4/16	3.44			3	4	4	3
Tannic acid	0.25- >64	4/16	3.17		1	3	1	5	3
Gallic acid	16- >64	16/16	19.02						
Rosmarinic acid	32- >64	32/32	32						
Chlorogenic acid	8- >64	12/27.2	13.45						
Caffeic	32	32/32	32						
Ferulic	16- >64	16/16	16						
P-coumaric	32- >64	32/32	32						

DISCUSSION

The development of antifungal resistance must be considered a serious public health problem, as it can significantly impact global health (8). Multidrug resistance and pandrug resistance in fungal pathogens, such as *C. auris*, azole-resistant *Aspergillus fumigatus*, and terbinafine- and azole-resistant dermatophytes are associated with poor health outcomes (7). These pathogens are often resistant to multiple or entire classes of available antifungal agents. The limited treatment options for managing fungal infections with drug-resistant phenotypes contribute to higher morbidity and mortality rates (8). Therefore, it is essential to focus on the design and development of new classes of antifungals and innovative therapeutic strategies. Among the phenolic compounds, tannic acid exhibited significant antifungal activity against *Candida* isolates. The MIC₅₀ and MIC₉₀ values for tannic acid and fluconazole against all *Candida* isolates were 4 µg/mL and 16 µg/mL, respectively. The results also showed that tannic acid demonstrated strong in vitro antifungal activity against non-*albicans* *Candida* isolates, as indicated by its GM MIC, which was significantly lower than the one for fluconazole. The reason for the difference in antifungal activities between tannic acid and the other polyphenolic compounds remains to be elucidated. However, the high number of hydroxyl groups in the structure of tannic acid may contribute to these differences (26). Therefore, the polyphenolic compounds and their interaction with the cell membrane can significantly affect and inhibit microbial functions (26). The antifungal activity of phenolic compounds has been documented in previously published studies, with significant variability in the MIC values. Therefore, the assessment of the results is challenging, as different methods have been applied for determining the antifungal activity of polyphenolics by researchers (27). The exact mechanisms of polyphenolic compounds against *Candida* species remain unknown. However, some researchers have suggested that the action of polyphenolics on *Candida* species may be due to their ability to penetrate the cell membrane and alter cell surface charge and hydrophobicity (28). Additionally, polyphenolics may interfere with 1,3-β-glucan synthase (29), significantly inhibit ergosterol biosynthesis (30) and induce the production of reactive oxygen species (ROS) (8). Furthermore, several factors influence the mechanisms by which

polyphenolics affect fungi, including inducing the induction of apoptotic mechanisms in *Candida* (31, 32) and the inhibition of efflux transporters (33). The progress of research in the upcoming years will be crucial. The compounds analysed in this study are just the beginning, however, they represent a significant step forward. To gain a more thorough understanding of the antifungal activity of tannic acid, in vitro testing should be expanded to include a wider range of drug-resistant *Candida* isolates. This would offer a more precise evaluation of its antifungal potential and help define the spectrum of activity of tannic acid against drug-resistant *Candida* species.

CONCLUSION

The increasing of antifungal resistance shows the importance of evaluating new drugs that are more robust to resistance mechanisms. Such studies should be of particular interest due to the increasing significance of resistance in both established and emerging fungi. This study indicated that tannic acid exhibits strong antifungal activity and could be considered a novel class of antifungal agents for treating fungal infections, including multidrug-resistant non-*albicans* *Candida* infections.

ACKNOWLEDGEMENTS

All authors report no potential conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This work is supported by grants from Iran University of Medical Sciences, Tehran, Iran (no. 1400-1-75-19967) and Isfahan University of Medical Sciences, Isfahan, Iran (no. 299172), which we gratefully acknowledge.

REFERENCES

1. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. *Nat Rev Dis Primers* 2018; 4: 18026.
2. Perlín DS. Antifungal drug resistance: do molecular methods provide a way forward? *Curr Opin Infect Dis* 2009; 22: 568-573.
3. Sanyaolu A, Okorie C, Marinkovic A, Abbasi AF,

- Prakash S, Mangat J, et al. *Candida auris*: an overview of the emerging drug-resistant fungal infection. *Infect Chemother* 2022; 54: 236-246.
4. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. *Am J Med* 2012; 125(1 Suppl): S3-S13.
5. Hashemi SE, Shokohi T, Abastabar M, Aslani N, Ghadamzadeh M, Haghani I. Species distribution and susceptibility profiles of *Candida* species isolated from vulvovaginal candidiasis, emergence of *C. lusitaniae*. *Curr Med Mycol* 2019; 5: 26-34.
6. Davari A, Hedayati MT, Jafarzadeh J, Nikmanesh B, Nabili M, Hamidieh AA, et al. Evaluation of *Candida* colonization index, molecular identification, and antifungal susceptibility pattern of *Candida* species isolated from critically ill pediatric patients: A single-center study in Iran. *Curr Med Mycol* 2022; 8: 15-21.
7. Banerjee S, Denning DW, Chakrabarti A. One Health aspects & priority roadmap for fungal diseases: A mini-review. *Indian J Med Res* 2021; 153: 311-319.
8. Sadeghi-Ghadi Z, Vaezi A, Ahangarkani F, Ilkit M, Ebrahimnejad P, Badali H. Potent in vitro activity of curcumin and quercetin co-encapsulated in nanovesicles without hyaluronan against *Aspergillus* and *Candida* isolates. *J Mycol Med* 2020; 30: 101014.
9. CDC (2019). Prevention. Antibiotic resistance threats in the United States. US Department of Health and Human Services, Centres for Disease Control Prevention. <https://ndc.services.cdc.gov/wp-content/uploads/Antibiotic-Resistance-Threats-in-the-United-States-2019.pdf>
10. Beardsley J, Halliday CL, Chen SC, Sorrell TC. Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside. *Future Microbiol* 2018; 13: 1175-1191.
11. Sanglard D. Emerging threats in antifungal-resistant fungal pathogens. *Front Med (Lausanne)* 2016; 3: 11.
12. Vaezi A, Fakhim H, Javidnia J, Khodavaisy S, Abtahian Z, Vojooodi M, et al. Pesticide behavior in paddy fields and development of azole-resistant *Aspergillus fumigatus*: should we be concerned? *J Mycol Med* 2018; 28: 59-64.
13. Daglia M. Polyphenols as antimicrobial agents. *Curr Opin Biotechnol* 2012; 23: 174-181.
14. Fraga CG, Croft KD, Kennedy DO, Tomás-Barberán FA. The effects of polyphenols and other bioactives on human health. *Food Funct* 2019; 10: 514-528.
15. Bouarab Chibane L, Degraeve P, Ferhout H, Bouajila J, Oulahal N. Plant antimicrobial polyphenols as potential natural food preservatives. *J Sci Food Agric* 2019; 99: 1457-1474.
16. Efenberger-Szmechtyk M, Nowak A, Czyzowska A. Plant extracts rich in polyphenols: Antibacterial agents and natural preservatives for meat and meat products. *Crit Rev Food Sci Nutr* 2021; 61: 149-178.
17. Olszewska MA, Gedas A, Simões M. Antimicrobial polyphenol-rich extracts: Applications and limitations in the food industry. *Food Res Int* 2020; 134: 109214.
18. Skroza D, Šimat V, Smole Možina S, Katalinić V, Boban N, Generalić Mekinić I. Interactions of resveratrol with other phenolics and activity against food-borne pathogens. *Food Sci Nutr* 2019; 7: 2312-2318.
19. Diba K, Makhdoomi K, Nasri E, Vaezi A, Javidnia J, Gharabagh DJ, et al. Emerging *Candida* species isolated from renal transplant recipients: species distribution and susceptibility profiles. *Microb Pathog* 2018; 125: 240-245.
20. Fakhim H, Chowdhary A, Prakash A, Vaezi A, Danaoui E, Meis JF, et al. In vitro interactions of echinocandins with triazoles against multidrug-resistant *Candida auris*. *Antimicrob Agents Chemother* 2017; 61(11): e01056-17.
21. Fakhim H, Emami S, Vaezi A, Hashemi SM, Faeli L, Diba K, et al. In vitro activities of novel azole compounds ATTAf-1 and ATTAf-2 against fluconazole-susceptible and-resistant isolates of *Candida* species. *Antimicrob Agents Chemother* 2016; 61(1): e01106-16.
22. Fakhim H, Vaezi A, Javidnia J, Nasri E, Mahdi D, Diba K, et al. *Candida africana* vulvovaginitis: Prevalence and geographical distribution. *J Mycol Med* 2020; 30: 100966.
23. Nasri E, Vaezi A, Falahatinejad M, Rizi MH, Sharifi M, Sadeghi S, et al. Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients. *Braz J Microbiol* 2023; 54: 143-149.
24. Nasri E, Fakhim H, Vaezi A, Khalilzadeh S, Ahangarkani F, Laal kargar M, et al. Airway colonisation by *Candida* and *Aspergillus* species in Iranian cystic fibrosis patients. *Mycoses* 2019; 62: 434-440.
25. Clinical and Laboratory Standards Institute (CLSI) (2017). Performance Standards for Antifungal Susceptibility Testing of Yeasts. 1st ed. CLSI supplement M60. https://clsi.org/media/1895/m60ed1_sample.pdf
26. Hodaei M, Rahimmalek M, Arzani A. Variation in bioactive compounds, antioxidant and antibacterial activity of Iranian Chrysanthemum morifolium cultivars and determination of major polyphenolic compounds based on HPLC analysis. *J Food Sci Technol* 2021; 58: 1538-1548.
27. Evensen NA, Braun PC. The effects of tea polyphenols on *Candida albicans*: inhibition of biofilm formation and proteasome inactivation. *Can J Microbiol* 2009; 55: 1033-1039.
28. Sung WS, Lee DG. Antifungal action of chlorogenic acid against pathogenic fungi, mediated by membrane disruption. *Pure Appl Chem* 2010; 82: 219-226.

29. Ma CM, Abe T, Komiyama T, Wang W, Hattori M, Daneshtalab M. Synthesis, anti-fungal and 1, 3- β -d-glucan synthase inhibitory activities of caffeic and quinic acid derivatives. *Bioorg Med Chem* 2010; 18: 7009-7014.
30. Ahmad A, Khan A, Manzoor N. Reversal of efflux mediated antifungal resistance underlies synergistic activity of two monoterpenes with fluconazole. *Eur J Pharm Sci* 2013; 48: 80-86.
31. Khan MS, Ahmad I. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against *Candida albicans* biofilms. *J Antimicrob Chemother* 2012; 67: 618-621.
32. Zore GB, Thakre AD, Jadhav S, Karuppayil SM. Terpenoids inhibit *Candida albicans* growth by affecting membrane integrity and arrest of cell cycle. *Phytomedicine* 2011; 18: 1181-1190.
33. Huang S, Cao YY, Dai BD, Sun XR, Zhu ZY, Cao YB, et al. In vitro synergism of fluconazole and baicalein against clinical isolates of *Candida albicans* resistant to fluconazole. *Biol Pharm Bull* 2008; 31: 2234-2236.